Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
Objective The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA). Method We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2020-09, Vol.39 (9), p.2583-2592 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2592 |
|---|---|
| container_issue | 9 |
| container_start_page | 2583 |
| container_title | Clinical rheumatology |
| container_volume | 39 |
| creator | Behrens, Frank Tony, Hans-Peter Koehm, Michaela Schwaneck, Eva C. Gnann, Holger Greger, Gerd Burkhardt, Harald Schmalzing, Marc |
| description | Objective
The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA).
Method
We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office.
Results
Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24).
Conclusions
Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment.
Trial registration
NCT01076205
Key Points
• Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis.
• Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high. |
| doi_str_mv | 10.1007/s10067-020-05038-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7426289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2433603398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-7f719e97cca2b52059f63c2de3fb6a60936c6cc4b2bf0aee2abcfabd0583eb883</originalsourceid><addsrcrecordid>eNp9kc2O1SAUxxujca6jL-DCkLhxU6XQC8WFiZn4lUziQl2TAz2dMralAr2Tvoorn8Unk3rH8WPhBhL4nf_h8CuKhxV9WlEqn8W8CllSRku6p7wp11vFrqp5XSpVq9vFjkpJS16p5qS4F-MlpZQ1qrpbnHDGqFCS74qvH5aYwE3YEjfOwR9wxCkRN5ErHz4TvyTrR4zbAY7z4NcMzpBchiK5cqknocdlhORdSyCkPrjkImmX4KYLwr5_WxFCJL4j0MLgxowaknoMMK_PCUzEm4jhkBP9BAOxvvchkZiWdr1f3OlgiPjgej8tPr1-9fHsbXn-_s27s5fnpa1lnUrZyUqhktYCM3tG96oT3LIWeWcECKq4sMLa2jDTUUBkYGwHpqX7hqNpGn5avDjmzosZsbV5tACDnoMbIazag9N_30yu1xf-oGXNRP7QHPDkOiD4LwvGpEcXLQ4DTOiXqBlvmBBVLbZej_9BL_0S8uSZqjkXlHO1UexI2eBjDNjdPKaielOvj-p1Vq9_qtdrLnr05xg3Jb9cZ4AfgThvcjD87v2f2B_ER8GA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2433603398</pqid></control><display><type>article</type><title>Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Behrens, Frank ; Tony, Hans-Peter ; Koehm, Michaela ; Schwaneck, Eva C. ; Gnann, Holger ; Greger, Gerd ; Burkhardt, Harald ; Schmalzing, Marc</creator><creatorcontrib>Behrens, Frank ; Tony, Hans-Peter ; Koehm, Michaela ; Schwaneck, Eva C. ; Gnann, Holger ; Greger, Gerd ; Burkhardt, Harald ; Schmalzing, Marc</creatorcontrib><description>Objective
The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA).
Method
We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office.
Results
Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24).
Conclusions
Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment.
Trial registration
NCT01076205
Key Points
• Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis.
• Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-020-05038-y</identifier><identifier>PMID: 32206973</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Absenteeism ; Adalimumab - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Cohort analysis ; Cohort Studies ; Efficiency ; Female ; Humans ; Immunotherapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Observational studies ; Original ; Original Article ; Patients ; Rheumatoid arthritis ; Rheumatology ; Sick Leave ; TNF inhibitors</subject><ispartof>Clinical rheumatology, 2020-09, Vol.39 (9), p.2583-2592</ispartof><rights>The Author(s) 2020. corrected publication 2020</rights><rights>The Author(s) 2020. corrected publication 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020, corrected publication 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-7f719e97cca2b52059f63c2de3fb6a60936c6cc4b2bf0aee2abcfabd0583eb883</citedby><cites>FETCH-LOGICAL-c474t-7f719e97cca2b52059f63c2de3fb6a60936c6cc4b2bf0aee2abcfabd0583eb883</cites><orcidid>0000-0002-3289-2299</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-020-05038-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-020-05038-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32206973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Behrens, Frank</creatorcontrib><creatorcontrib>Tony, Hans-Peter</creatorcontrib><creatorcontrib>Koehm, Michaela</creatorcontrib><creatorcontrib>Schwaneck, Eva C.</creatorcontrib><creatorcontrib>Gnann, Holger</creatorcontrib><creatorcontrib>Greger, Gerd</creatorcontrib><creatorcontrib>Burkhardt, Harald</creatorcontrib><creatorcontrib>Schmalzing, Marc</creatorcontrib><title>Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Objective
The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA).
Method
We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office.
Results
Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24).
Conclusions
Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment.
Trial registration
NCT01076205
Key Points
• Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis.
• Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high.</description><subject>Absenteeism</subject><subject>Adalimumab - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Efficiency</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Observational studies</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Sick Leave</subject><subject>TNF inhibitors</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc2O1SAUxxujca6jL-DCkLhxU6XQC8WFiZn4lUziQl2TAz2dMralAr2Tvoorn8Unk3rH8WPhBhL4nf_h8CuKhxV9WlEqn8W8CllSRku6p7wp11vFrqp5XSpVq9vFjkpJS16p5qS4F-MlpZQ1qrpbnHDGqFCS74qvH5aYwE3YEjfOwR9wxCkRN5ErHz4TvyTrR4zbAY7z4NcMzpBchiK5cqknocdlhORdSyCkPrjkImmX4KYLwr5_WxFCJL4j0MLgxowaknoMMK_PCUzEm4jhkBP9BAOxvvchkZiWdr1f3OlgiPjgej8tPr1-9fHsbXn-_s27s5fnpa1lnUrZyUqhktYCM3tG96oT3LIWeWcECKq4sMLa2jDTUUBkYGwHpqX7hqNpGn5avDjmzosZsbV5tACDnoMbIazag9N_30yu1xf-oGXNRP7QHPDkOiD4LwvGpEcXLQ4DTOiXqBlvmBBVLbZej_9BL_0S8uSZqjkXlHO1UexI2eBjDNjdPKaielOvj-p1Vq9_qtdrLnr05xg3Jb9cZ4AfgThvcjD87v2f2B_ER8GA</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Behrens, Frank</creator><creator>Tony, Hans-Peter</creator><creator>Koehm, Michaela</creator><creator>Schwaneck, Eva C.</creator><creator>Gnann, Holger</creator><creator>Greger, Gerd</creator><creator>Burkhardt, Harald</creator><creator>Schmalzing, Marc</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3289-2299</orcidid></search><sort><creationdate>20200901</creationdate><title>Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study</title><author>Behrens, Frank ; Tony, Hans-Peter ; Koehm, Michaela ; Schwaneck, Eva C. ; Gnann, Holger ; Greger, Gerd ; Burkhardt, Harald ; Schmalzing, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-7f719e97cca2b52059f63c2de3fb6a60936c6cc4b2bf0aee2abcfabd0583eb883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Absenteeism</topic><topic>Adalimumab - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Efficiency</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Observational studies</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Sick Leave</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Behrens, Frank</creatorcontrib><creatorcontrib>Tony, Hans-Peter</creatorcontrib><creatorcontrib>Koehm, Michaela</creatorcontrib><creatorcontrib>Schwaneck, Eva C.</creatorcontrib><creatorcontrib>Gnann, Holger</creatorcontrib><creatorcontrib>Greger, Gerd</creatorcontrib><creatorcontrib>Burkhardt, Harald</creatorcontrib><creatorcontrib>Schmalzing, Marc</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Behrens, Frank</au><au>Tony, Hans-Peter</au><au>Koehm, Michaela</au><au>Schwaneck, Eva C.</au><au>Gnann, Holger</au><au>Greger, Gerd</au><au>Burkhardt, Harald</au><au>Schmalzing, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>39</volume><issue>9</issue><spage>2583</spage><epage>2592</epage><pages>2583-2592</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Objective
The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA).
Method
We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office.
Results
Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24).
Conclusions
Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment.
Trial registration
NCT01076205
Key Points
• Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis.
• Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32206973</pmid><doi>10.1007/s10067-020-05038-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3289-2299</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2020-09, Vol.39 (9), p.2583-2592 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7426289 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Absenteeism Adalimumab - therapeutic use Arthritis, Rheumatoid - drug therapy Cohort analysis Cohort Studies Efficiency Female Humans Immunotherapy Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Observational studies Original Original Article Patients Rheumatoid arthritis Rheumatology Sick Leave TNF inhibitors |
| title | Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A47%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20improvement%20in%20work%20outcomes%20in%20employed%20patients%20with%20rheumatoid%20arthritis%20during%202%C2%A0years%20of%20adalimumab%20therapy:%20an%20observational%20cohort%20study&rft.jtitle=Clinical%20rheumatology&rft.au=Behrens,%20Frank&rft.date=2020-09-01&rft.volume=39&rft.issue=9&rft.spage=2583&rft.epage=2592&rft.pages=2583-2592&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-020-05038-y&rft_dat=%3Cproquest_pubme%3E2433603398%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2433603398&rft_id=info:pmid/32206973&rfr_iscdi=true |